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ORIGINAL ARTICLES
Effect of Obesity, Serum Lipoproteins, and Apolipoprotein
E Genotypes on Mortality in Hospitalized Elderly Patients
Filomena Addante,1 Daniele Sancarlo,1 Massimiliano Copetti,2 Carlo Scarcelli,1
Maria Grazia Longo,1 Valeria Niro,1 Giulia Paroni, 1 Fabio Pellegrini,2,3
Luigi Fontana,4 and Alberto Pilotto1
Abstract
Background: The aim of this study was to investigate the relationship among apolipoprotein E (APOE) poly-
morphism, body mass index (BMI), and dyslipidemia and how these factors modify overall mortality in a cohort
of hospitalized elderly patients.
Methods: Plasma concentrations of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), BMI, and APOE genotype were evaluated in 1,012
hospitalized elderly patients, who were stratified into three groups according to their baseline BMI and APOE
allele status. Multivariate logistic regression analysis was used to assess whether APOE genotype, BMI, and
dyslipidemia are associated with mortality, adjusting for potential confounders. Interaction analysis was also
performed.
Results: Obese patients have significantly higher levels of TC and LDL-C compared to normal-weight and
overweight subjects, for both sexes. APOE e4 carriers have significantly higher levels of TC and LDL-C com-
pared with e2 and e3 carrier both in males and females. Interaction analysis showed that women with
TC< 180mg/dL, LDL-C< 100mg/dL, normal weight, and e3 carrier (odds ratio [OR]¼ 3.42, 95% confidence
interval [CI] 1.36–8.60) and men with LDL-C< 100mg/dL, HDL-C< 40mg/dL, and e3 carrier (OR¼ 1.97, 95%
CI 1.04–3.74) were at highest risk of mortality.
Conclusions: In elderly hospitalized patients, obesity and APOE genotype influence the lipid profile and mor-
tality risk. A significant interaction among BMI, dyslipidemia, and APOE genotype was observed that could
identify elderly patients with different risks of mortality.
Introduction
Excessive body weight is associated at all ages withdetrimental changes in the lipid profile. Higher body
mass index (BMI), a surrogate measurement of total body fat,
is associated with higher plasma concentrations of total
cholesterol (TC), low-density lipoprotein cholesterol (LDL-
C), and triglycerides (TG).1 Data from several epidemiolog-
ical studies have also shown that apolipoprotein E (APOE)
polymorphism is associated with variation of serum TC and
LDL-C concentrations.2,3 APOE is a multifunctional glyco-
protein that plays a key role in regulating lipoprotein me-
tabolism and cardiovascular risk.4 The APOE gene exhibits a
genetic polymorphism with three common alleles ( e2, e3,
and e4), which encode for three protein isoforms E2, E3, and
E4.5 APOE polymorphism has been related to significant
modifications of the lipoprotein profile, with the e2 allele
being associated with lower and the e4 allele with higher TC
and LDL-C levels than the e3 allele.6,7 Isoform-specific effects
include the association of APOE e4 with increased risk for
atherosclerosis, stroke, impaired cognitive function, and
Alzheimer disease (AD).7,8–10 Moreover, some11,12 but not all,
population-based studies13,14 have found a negative or pos-
itive association between mortality risk and APOE e2 and
APOE e3 polymorphisms, respectively. However, to the best
of our knowledge, no study has investigated the interaction
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between APOE polymorphism, BMI, and dyslipidemia in a
large cohort of hospitalized elderly patients, in whom the
aging process and co-morbidity may have profound effects
on body composition and lipid metabolism.
The purpose of the present study was to evaluate the re-
lationship among APOE polymorphism, adiposity, and
dyslipidemia in a large group of elderly patients who were
admitted to our hospital. A second aim was to study how
these factors affect prognosis by modifying overall mortality.
Methods
Study design
From January, 2006, to March, 2007, all patients consecu-
tively admitted to the Geriatrics Unit of the ‘‘Casa Sollievo
della Sofferenza’’ Hospital, IRCCS, San Giovanni Rotondo,
Italy, were screened for inclusion in the study. Inclusion cri-
teria were: (1) Caucasian race, (2) age 65 years; (3) ability to
provide an informed consent or availability of a proxy for
informed consent. Exclusion criteria were: (1) Diagnosis of
neoplasms; (2) medical/surgical hospitalization within 1
month before the study; (3) use of lipid-lowering drugs during
the previous 4 weeks. Patients with AD were included in the
study. Diagnoses of possible/probable AD were made ac-
cording to the criteria of the National Institute of Neurological
and Communicative Disorders and Stroke–Alzheimer’s Dis-
ease and Related Disorders AssociationWork Group (NINDS-
ADRDA).15 This study was approved by the Human Studies
Committee of ‘‘Casa Sollievo della Sofferenza’’ Hospital,
IRCCS, San Giovanni Rotondo, Italy, and all subjects gave
informed consent before their participation.
All measurements were performed during the hospital
admission examination. Height was measured without shoes
to the nearest 0.1 cm. Body weight was obtained on a balance
scale in the morning after subjects fasted for 12 h overnight.
BMI was calculated by dividing body weight (in kilograms)
by the square of height (in meters). According to the Na-
tional Institutes of Health (NIH) guidelines, normal weight
was defined as a BMI 18.5 and 24.9 kg/m2, overweight
as a BMI 25 and 29.9 kg/m2, and obesity as a BMI
 30 kg/m2.16
Information on the vital status of the participants was
obtained at regular intervals from the municipal population
registries located in the towns where the patients resided at
the time of hospital admission. Mortality data were available
up to January 31, 2009.
Laboratory analysis
A venous blood sample was taken to determine lipid and
lipoprotein concentrations, and APOE genotypes after sub-
jects had fasted for at least 12 h. Plasma levels of TC, TG,
LDL-C, and high-density lipoprotein cholesterol (HDL-C)
were measured by standardized enzymatic procedures and
expressed in mg/dL.
Genetic analysis
Genomic DNA was purified manually from peripheral
blood by organic protein extraction and ethanol precipitation
according to a standard method. The APOE genotypes were
determined by polymerase chain reaction (PCR) and agarose
gel electrophoresis as described previously.17 Briefly, a
combination of four specific primers in three different pairs
sharing the same stringent PCR conditions was used. Allele-
specific primers were: ASP1, CGG ACA TGG AGG ACG
TGT; ASP2, CGG ACA TGG AGG ACG TGC; ASP3, CTG
GTA CAC TGC CAG GCG; and ASP4, CTG GTA CAC TGC
CAG GCA, synthesized by Invitrogen (Invitrogen Corpora-
tion, Carlsbad, CA). The primer pair ASP-1/ASP-4 identifies
the e2 allele, the primer pair ASP-1/ASP-3 identifies the e3
allele, and the primer pair ASP-2/ASP-3 identifies the e4
allele. On an Applied Biosystems GeneAmp PCR System
9700, the amplification conditions were 948C for 2min, fol-
lowed by 32 cycles at 968C for 15 sec, 618C for 30 sec, and
728C for 30 sec. Reaction buffer included 1.5U of Taq DNA
polymerase (PlatinumTaq, Invitrogen, Carlsbad, CA), 10
pmoles of each primer, 100 picomoles (pM) nucleoside tri-
phosphates (NTPs), and 1mM MgCl2. The presence/absence
of specific allele PCR products detected by electrophoresis
analysis on a 2% agarose gel identified the six APOE geno-
types. Patients were classified into the following three phe-
notype groups: APOE e2, e3, and e4 groups. The e3/ e3
genotype was the reference category; subjects with the e2/ e2
or e2/ e3 genotypes were considered e2þ carriers and sub-
jects with e3/ e4 or e4/ e4 genotypes were considered e4þ
carriers. Subjects who were carriers of the e2/ e4 genotype
were excluded from the analysis.
Statistical analysis
Patients’ baseline characteristics were reported as
mean standard deviation (SD) or frequencies and percent-
ages for continuous and categorical variables, respectively.
Baseline comparison between men and women was made
using the chi-squared test for categorical variables and the
Mann–Whitney U-test for continuous variables. Baseline
differences according to BMI groups and APOE alleles
groups were assessed with the analysis of variance (ANOVA)
F-test or chi-squared test for continuous and categorical
variables, respectively. p values for trend were estimated
using the Mantel–Haenszel chi-squared test and ANOVA
F-test for trend, appropriately. Genotype distribution ac-
cording to the Hardy–Weinberg equilibrium was analyzed
by the exact chi-squared test.
Multivariate logistic regression analysis was performed to
investigate, separately, the association between BMI, dysli-
pidemia, APOE polymorphism, and all-cause mortality. The
following cutoffs were used to dichotomize dyslipidemia
variables: 180mg/dL for TC, 100mg/dL for LDL-C, 150mg/
dL for TG, 40mg/dL for HDL-C in men, and 50mg/dL for
HDL-C in women. Results were shown and odds ratio (OR)
along their 95% confidence interval (95% CI).
Furthermore, to evaluate interactions among covariates and
identify distinct and homogeneous subgroups of patients in
terms of mortality, the REPCAM method was used.18 This
tree-based method integrates the advantages of main-effects
logistic regression and tree-growing techniques. At each par-
titioning step, the method chooses the covariate and its best
binary split to maximize the difference in the outcome of in-
terest. The algorithm stops when user-defined conditions
(stopping rules) are met. To obtain a more robust and stable
split, a permutation approach was adopted to choose the best
splitting variable. Global adjustment for age, diabetes, AD,
and cardiovascular diseases was accounted for.
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All analyses were performed separately for males and
females. All analyses were performed using SAS release 9.1.
For the RECPAM analysis, we used an SAS macroroutine
written by F. Pellegrini. p values <0.05 were considered
significant.
Results
Study population
From January, 2006, to March, 2007, 1,129 patients were
admitted consecutively to the Geriatric Unit of ‘‘Casa Sol-
lievo della Sofferenza’’ Hospital in San Giovanni Rotondo
(FG). Of the 1,129 patients assessed for eligibility, 72 patients
were excluded because they were younger than 65 years, and
28 refused to participate. Because only 7 patients had a BMI
value less than 18.5, they were excluded from the analysis.
Thus, 1,022 patients (494 men and 528 women) with a mean
age of 77.6 6.7 years (range 65–100 years), were eligible for
the present investigation. Table 1 reports the characteristics
of patients included in the study, divided according to gen-
der. Female patients had significantly higher BMI mean
values, higher serum TC, LDL-C, and HDL-C concentrations,
and a higher prevalence of hypertension than male patients
( p¼ 0.0001). Age, serum TG concentration, and the preva-
lence of diabetes mellitus and AD were not significantly
different between male and female patients. The distribution
of the different APOE polymorphisms among all subjects
was as follows: 11.5% for the e2/e3 genotype (n¼ 118), 71.2%
for the e3/e3 genotype (n¼ 728), 15.3% for the e3/e4 geno-
type (n¼ 157), 0.88% for the e4/e4 genotype (n¼ 9), and 0.9%
for the e2/e4 genotype (n¼ 10). No e2/e2 APOE genotypes
were observed. Patients with the e2/e4 genotype (n¼ 10)
were not considered in the analysis. The observed genotype
frequency distributions did not show statistically significant
differences compared with those expected under Hardy–
Weinberg equilibrium ( p¼ 0.106). Estimated allele frequen-
cies were 0.062 for the e2 allele, 0.846 for the e3 allele, and
0.085 for the e4 allele. The distribution of the APOE genotype
frequencies was not significantly different between males
and females (Table 1).
Table 2 shows the mean levels of serum lipids in patients,
divided according to BMI and gender. The effect of BMI on
serum lipid concentrations was studied by using BMI classes
(normal weight, overweight, and obese). The mean value of
BMI in the general population is 27.5 5.1 kg/m2; 336
(33.2%) patients were normal weight, 399 (39.4%) were
overweight, and 277 (27.4) were obese according to their
baseline BMI. In both male and female patients, BMI was
significantly associated with serum concentrations of TC and
LDL-C, but not with HDL-C. BMI was significantly associ-
ated with serum concentration of TG only in males.
APOE polymorphism, plasma lipid, lipoprotein
concentrations, and BMI
The bioclinical characteristics according to APOE poly-
morphisms are summarized in Table 3. No difference in the
mean age of the patients across the APOE polymorphisms
was observed. In both male and female patients, the mean
concentrations of TC and LDL-C were APOE genotype de-
pendent; APOE e4 carriers had significantly higher levels of
TC and LDL-C compared to e2 and e3 carriers. In contrast,
there were no significant differences among APOE geno-
types in plasma concentrations of HDL-C and TG. The effect
of APOE alleles on BMI was studied by using BMI as a
continuous variable or by using BMI classes (normal weight,
overweight, and obese). In both male and female patients,
Table 1. Baseline Characteristics of Patients Divided According to Gender
Total (n¼ 1022) Men (n ¼ 494) Women (n¼ 528) p
Mean age (years, mean SD) 77.6 6.7 77.4 6.7 77.7 6.7 0.490
BMIa (kg/m2, mean SD) 27.5 5.1 26.7 4.3 28.3 5.6 0.000
Diabetes mellitusa 206 (20.1) 92 (18.6) 114 (21.6) 0.274
Hypertensiona 411 (40.2) 161 (32.6) 250 (47.3) 0.000
Ischemic cardiomiopathya 87 (8.5) 54 (10.9) 33 (6.2) 0.007
Alzheimer dementia 180 (17.8) 83 (17.0) 97 (18.5) 0.532
Total cholesterolb 165.9 45.7 158.4 44.0 173.5 45.9 0.000
LDL-Cb 100.9 36.7 95.9 36.7 105.6 36.0 0.000
HDL-Cb 39.5 14.9 37.1 13.5 41.8 15.8 0.000
Triglycerides (TG)b 119.1 66.5 115.3 62.9 122.6 69.5 0.083
Allele frequencies (%)
e3( %) 84.6 84.6 85.4 0.657
e4(%) 8.5 8.1 9.9 0.180
e2(%) 6.2 7.1 5.4 0.134
Genotype frequencies
e 3/e 3a 728 (71.2) 349 (70.6) 379 (71.7) 0.749
e 2/e 3a 118 (11.5) 65 (13.1) 53 (10.0) 0.148
e 4/e 3a 157 (15.3) 73 (14.8) 84 (15.9) 0.688
e 4/e 4a 9 (0.88) 1 (0.2) 8 (1.5) 0.140
e 2/e 4a 10 (0.9) 6 (1.2) 4 (0.7) 0.615
1 year mortalitya 161 (15.9) 94 (19.3) 67 (12.8) 0.005
aData are N8 (%).
bData are mg/dL.
SD, Standard deviation; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C high-density lipoprotein.
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there was no significant difference among APOE genotypes
between normal-weight, overweight, and obese patients
(Table 3).
Mortality data
A total of 161 deaths (15.9%) occurred during the follow
up. Males had significantly higher mortality rates than fe-
males (19.3% vs. 12.8%, p¼ 0.005). Female patients who died
had significantly lower mean BMI than female patients who
survived (BMI¼ 26.8 5.2 vs. 28.5 5.7, p¼ 0.018); this dif-
ference was not found in male patients (BMI¼ 26.1 4.3 vs.
26.8 4.2, p¼ 0.118). Mortality was significantly higher in
normal weight patients than obese patients both in males
(40.4% vs. 20.2%, p for trend¼ 0.001) and female (41.8% vs.
25.4%; p for trend¼ 0.001). Male patients who died had a
significantly lower level of LDL-C (85.8 38.5 vs. 98.2 35.9;
p¼ 0.003) and HDL-C (34.5 15.4 vs. 37.7 12.9; p¼ 0.041)
than patients who survived, whereas TC (151.1 47.0 vs.
159.5 43.1; p¼ 0.095) and TG levels (118.4 67.4 vs.
113.8 60.2; p¼ 0.540) did not differ significantly. In female
patients, levels of TC (147.6 47.7 vs. 177.16 44.7;
p¼ 0.000), LDL-C (92.8 36.8 vs. 107.6 35.4; p¼ 0.002), and
HDL-C (37.3 14.7 vs. 42.6 15.9; p¼ 0.016) were signifi-
cantly lower in patients who died compared to survivors.
The APOE e2 carriers had lower mortality compared with
APOE e3 and e4 carriers both in males (8.5% vs. 75.5% vs.
16%) and females (6% vs. 80.6% vs. 13.4%) (Table 4). No
significant differences in the prevalence of AD were ob-
served between patients who died versus survivors.
Multivariate logistic regression analysis, adjusted for
several confounding factors, indicates that obesity
(OR¼ 0.486, 95% CI 0.255–0.927, p¼ 0.028), TC> 180mg/dL
(OR¼ 0.350, 95% CI 0.187–0.657, p¼ 0.001), and LDL-
C> 100mg/dL (OR¼ 0.456, 95% CI 0.235–0.882; p¼ 0.020)
are factors significantly associated with a lower risk of
mortality in female patients. These associations were not
observed in male patients. No significant association be-
tween APOE genotype, higher TG, lower HDL-C level, and
1-year mortality was observed (Table 5).
Interactions
To investigate the interaction between APOE genotype,
BMI, lipid levels, and mortality, a RECPAM analysis was
performed separately for males and females leading to the
Table 2. Lipid Levels in Patients Divided According to BMI Classes
Men (n¼ 488) Women (n¼ 524)
Normal weight
(n¼ 180)
Overweight
(n¼ 208)
Obese
(n¼ 100) p
Normal weight
(n¼ 156)
Overweight
(n¼ 191)
Obese
(n¼ 177) p
TC 152.1 42.4 159.1 44.5 165.9 44.3 0.038 a 164.3 43.8 179.9 46.0 174.3 47.3 0.007 a
TG 101.2 47.7 122.3 66.0 123.1 70.1 0.001b 115.7 73.4 117.6 60.1 131.8 69.1 0.054b
HDL-C 38.2 14.7 36.3 13.7 36.9 10.5 0.392 43.2 17.4 41.1 13.5 41.6 16.9 0.462
LDL-C 91.1 35.9 96.3 38.5 103.1 36.7 0.033c 96.8 35.8 111.2 35.6 107.6 34.8 0.001c
Data are mean standard deviation (SD), mg/dL.
aMen: normal weight vs, obese, p¼ 0.036; women: normal weight vs. overweight, p¼ 0.005.
bMen: normal weight vs. overweight, p¼ 0.002; normal weight vs, obese, p¼ 0.013.
cMen: normal weight vs. obese, p¼ 0.028; women: normal weight vs. overweight, p¼ 0.001; normal weight vs. obese, p¼ 0.020.
BMI, body mass index; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol.
Table 3. Serum Lipid Levels and BMI Distribution in Patients Divided According
to Their APOE Allele Status
Men Women
e2/ (n¼ 65) e3/e3 (n¼ 349) e4/ (n¼ 74) p e2/ (n ¼ 53) e3/e3 (n¼ 379) e4/ (n¼ 92) p
Age 77.9 6.9 77.2 6.6 78.3 6.6 0.360 77.2 6.5 77.9 6.7 77.4 6.5 0.671
TCa (mg/dL) 141.8 42.5 159.4 42.2 164.9 50.1 0.004b 164.8 51.4 172.1 45.1 183.4 46.0 0.039
TGa (mg/dL) 116.8 71.9 115.9 57.6 106.8 69.8 0.489 116.5 57.1 118.9 63.1 136.9 87.7 0.061
HDL-Ca (mg/dL) 36.5 11.9 36.6 13.4 39.8 15.0 0.183 40.8 15.2 42.4 14.5 40.3 21.7 0.472
LDL-Ca (mg/dL) 80.7 34.9 97.7 36.2 100.8 38.0 0.001c 90.8 33.9 106.9 34.7 109.5 35.8 0.006c
BMIa (kg/m2) 26.9 3.7 26.8 4.3 26.1 4.3 0.419 28.9 5.6 28.3 5.6 27.9 6.2 0.639
Normalweightd 19 (29.2) 129 (37.0) 32 (43.2) 0.088 15 (28.3) 111 (29.3) 30 (32.6) 0.534
Overweightd 33(50.8) 146 (41.8) 29 (39.2) 0.178 17 (32.1) 141 (37.2) 33 (35.9) 0.755
Obesed 13 (20.0) 74 (21.2) 13 (17.6) 0.698 21 (39.3) 127 (33.5) 29 (31.5) 0.358
aData are mean standard deviation.
bMen: e2 vs. e3/ e3, p¼ 0.009; e2 vs. e4, p¼ 0.006.
cMen: e2 vs. e3/e3, p¼ 0.002; e2 vs. e4, p¼ 0.004; women: e2 vs. e3/e3, p¼ 0.008; e2 vs. e4, p¼ 0.009.
dData are N8 (%).
BMI, body mass index; APOE, apolipoprotein E; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-
C, low-density lipoprotein cholesterol.
114 ADDANTE ET AL.
identification of five classes of patients at different risk of
mortality (Fig. 1A,B). The reference category was represented
by the subgroup with the lowest mortality. Thus, the ORs for
all the other subgroups were estimated with respect to the
reference class.
In females, the most important variable in discriminating
the risk of death was represented by the TC, with the low-
est mortality in patients with values of TC greater than
180mg/dL. On the opposite side of the regression tree, pa-
tients APOE e3 carriers, LDL-C values lower than 100mg/dL
and with a normal weight represented the subgroup with the
highest mortality (OR¼ 3.42, 95% CI¼ 1.36–8.60). The class
of patients with TC lower than 180mg/dL APOE e3 carrier
but with LDL-C greater than 100mg/dL showed a signifi-
cant risk of mortality (OR¼ 2.59, 95% CI 1.09–6.18). For pa-
tients showing a TC lower than 180mg/dL, APOE e3 carrier,
a LDL-C lower than 100mg/dL but overweight or obese, the
estimated OR¼ 3.17 (95% CI 1.42–7.08). Patients’ age
( p< 0.001) and presence of diabetes ( p¼ 0.70), AD, and
cardiovascular diseases ( p¼ 0.47) were included in the
model as global adjustment variables.
In males, the class of patients with lowest mortality were
those with LDL-C higher than 100mg/dL and overweight or
obese. On the opposite side of the regression tree, patients
with LDL-C lower than 100mg/dL, HDL lower than 40mg/
dL, and APOE e3 carrier showed the highest mortality
(OR¼ 1.97, 95% CI 1.04–3.74). Patients’ age ( p¼ 0.057),
presence of diabetes ( p¼ 0.175), AD, and cardiovascular
disease ( p¼ 0.062) were included in the model as global
adjustment variables.
Discussion
The detection of gene–environment interactions can pro-
vide key information on the biological mechanisms of dis-
eases and can lead to new insights into the prevention,
diagnosis, and treatment of chronic diseases in specific sub-
groups of the population. In this study, we evaluated the
relationship among APOE polymorphism, BMI, and dysli-
pidemia and how these factors modify overall mortality risk.
In agreement with previous studies,19,20 we found that the
mean concentrations of TC and LDL-C were APOE genotype
and BMI dependent in both male and female elderly patients.
In this study, TC and LDL-C levels were significantly higher
in obese than in normal weight patients, and in subjects
carrying e4 compared to subjects carrying e2 and e3 in both
males and females patients. In contrast, we did not find a
significant association between APOE alleles and serum
HDL-C concentrations in both men and women. A signifi-
cant association between APOE polymorphism and HDL-C
Table 4. Baseline Characteristics of Men and Women by Vital Status
Men Women
Survivors
(n¼ 394)
Decedents
(n¼ 94) p
Survivors
(n¼ 457)
Decedents
(n ¼ 67) P
BMIa (kg/m2) 26.8 4.2 26.1 4.3 0.118 28.5 5.7 26.8 5.2 0.018
Normal weightb 142 (36.0) 38 (40.4)
p for trend 0.001
128 (28.0) 28 (41.8)
p for trend 0.003
Overweightb 171 (43.4) 37 (39.4) 169 (37.0) 22 (32.8)
Obeseb 81 (20.6) 19 (20.2) 160 (35.0) 17 (25.4)
Alzheimer diseaseb 73 (18.5) 10 (10.6) 0.219 88 (19.3) 9 (13.4) 0.082
e2 carrierb 57 (14.5) 8 (8.5) 0.127 49 (10.7) 4 (6) 0.228
e3 carrierb 273 (70.6) 71 (75.5) 0.337 325 (71.1) 54 (80.6) 0.105
e4 carrierb 59 (15) 15 (16) 0.811 83 (18.2%) 9 (13.4) 0.342
TCa (mg/dL) 159.5 43.1 151.1 47.0 0.095 177.16 44.7 147.6 47.7 0.000
LDL-Ca (mg/dL) 98.2 35.9 85.8 38.5 0.003 107.6 35.4 92.8 36.8 0.002
HDL-Ca (mg/dL) 37.7 12.9 34.5 15.4 0.004 42.6 15.9 37.3 14.7 0.016
TGa (mg/dL) 113.8 60.2 118.4 67.4 0.540 120.9 64.8 128.4 85.4 0.394
aData are mean standard deviation.
bData are N8 (%).
BMI, Body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG,
triglycerides.
Table 5. Risk Factor for 1-Year Mortality
According to Gender
OR (95% CI)
Men Women
Normal weight 1 (reference) 1 (reference)
Overweight 0.809 (0.488–1.339) 0.595 (0.325–1.088)a
Obese 0.877 (0.474–1.621) 0.486 (0.255–0.927)a
e2 carrier 0.598 (0.270–1.104) 0.323 (0.094–1.119)b
e3 carrier 1 (reference) 1 (reference)
e4 carrier 1.024 (0.542–1.936) 0.883 (0.404–1.931)b
Hypercholesterolemia 0.819 (0.488–1.374) 0.350 (0.187–0.657)c
High LDL-C 0.860 (0.496–1.492) 0.456 (0.235–0.882)c
High TG 1.197 (0.673–2.130) 1.316 (0.675–2.568)d
Lower HDL-C 1.640 (0.778–3.458) 1.338 (0.768–2.330)e
aData were adjusted for age, diabetes, dyslipidemia, and cardio-
vascular disease.
bData were adjusted for total-cholesterol and LDL-C levels and
Alzheimer disease.
cData were adjusted for age, BMI, cardiovascular disease; APOE
genotype.
dData were adjusted for age, BMI, and diabetes.
eData were adjusted for age and cardiovascular disease.
OR, Odds ratio; CI, confidence interval; LDL-C, low-density
lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density
lipoprotein cholesterol; BMI, body mass index; APOE, apolipopro-
tein E.
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has been reported in some studies21 but not in others.22
Discrepancies among different studies may be due to other
factors that regulate the gene–environment interaction af-
fecting HDL-C levels, such as physical activity, alcohol
consumption, and smoking.
In this population, no significant association between
APOE polymorphism and obesity was found. Only a few
studies have examined the relationship between APOE
polymorphisms and obesity. Although a significant associa-
tion between APOE e4 allele status and obesity was reported
in children and young adults,23 other studies failed to find a
significant difference in the APOE allele and genotype fre-
quencies between obese and nonobese subjects.24 In addi-
tion, none of these studies included hospitalized elderly
patients. A possible explanation for the lack of association
between BMI and APOE polymorphism in our population is
that BMI may be a poor indicator of obesity in elderly per-
sons because body composition varies with age.
In addition, we found that, unlike in nonelderly patients,
higher levels of TC in females and LDL-C in males are as-
sociated with a lower risk of mortality. This paradoxical re-
sult is in line with previous reports showing that
FIG. 1. Identification of subgroups at different risks for mortality: Results of RECPAM analysis. REPCAM analysis iden-
tified patient subgroups at different risks for mortality. The tree-growing algorithm modeled odds ratios (OR) after a logistic
regression with age, diabetes, and ischemic cardiomyopathy as global variables. Splitting variables are shown between
branches, whereas a condition sending patients to left or right sibling is on a relative branch. Class 1 with lowest mortality
was the reference category (OR¼ 1). Circles indicate subgroups of patients; squares indicate the patient subgroup REPCAM
class. Numbers inside circles and squares represent the number of events (top) and the number of nonevents (bottom),
respectively. (A) Females. Global adjustment variables: Age OR¼ 1.11 (1.06–1.16, diabetes OR¼ 1.15 (0.57–2.34, ischemic
cardiomyopathy OR¼ 0.71 (0.28–1.81. (B) Males. Global adjustment variables: Age OR¼ 1.03 (1.00–1.07), diabetes OR¼ 1.59
(0.81–3.08), ischemic cardiomyopathy OR¼ 0.52 (0.26–1.03).
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hypercholesterolemia is associated with lower mortality in
elderly patients.25–27 There are several potential explanations
for these findings. It is possible that subjects with higher
cholesterol levels died before recruitment and that the sam-
ple represents a group of healthy survivors with traits that
make them less susceptible to disease caused by high cho-
lesterol levels. Moreover, it is well known that cholesterol
levels decrease with age, and it has been suggested that low
cholesterol levels in the elderly represent a surrogate marker
of frailty or subclinical disease.28
In the present study, multivariate regression analysis shows
a negative relationship between BMI and mortality; and the
interaction analysis revealed that overweight and obesity are
protective in both males and females, even if with a different
grade of interaction, as suggested by the different composition
of the RECPAM tree-based algorithm, adjusted for age, dia-
betes, and AD or cardiovascular disease. These findings are in
agreement with previous studies.29–31 Several hypotheses
have been made to explain this effect of BMI on mortality in
the elderly: (1) The relationship among BMI, body fat, and fat
distribution weaken with aging; (2) lean mass and fat mass act
as important nutritional reserve during prolonged illness and
may be particularly important in old age as the incidence and
significance of illness and disease increase; (3) individuals
susceptible to the ill effects of elevated BMI may have already
died, determining a selective survival.
This study has limitations. First, our study evaluated the
interaction among APOE polymorphisms, BMI, dyslipide-
mia, and mortality risk, but did not evaluate the serum
concentrations of APOE, which has been shown to influence
the levels of circulating lipids.32 Second, in our study, we
used BMI as marker of obesity, instead of waist circumfer-
ence or trunk fat mass measured by dual-energy X-ray ab-
sorptiometry (DEXA), which are better predictors of
mortality in old age.33 Finally, the use of hospitalized elderly
patients does not allow us to exclude that demographic se-
lection could play a role in the reported differences. In con-
clusion, in elderly hospitalized patients, obesity and APOE
genotype influence the lipid profile and mortality risk. A
significant interaction among BMI, dyslipidemia, and APOE
genotype was observed that could identify elderly patients
with different risks of mortality.
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